# RISE Adult Medication Study

Study · id `cardio:ct-nct01779362` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01779362](<https://clinicaltrials.gov/study/NCT01779362>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01779362

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

## Technical summary

Registry record NCT01779362. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2019-02 (actual). Results posted on 2023-05-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 267 participants (enrolled count; ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Primary completion: 2019-02 (actual) (ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Completion: 2019-08 (actual) (ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Results first posted: 2023-05-11 (ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01779362, source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01779362-2023-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: RISE Adult Medication Study
- Acronym: RISE Adult
- Condition: Prediabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): Liraglutide
- Intervention (Drug): Glargine
- Intervention (Drug): Placebo
- Lead sponsor: RISE Study Group
- Lead sponsor class: NETWORK
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: a5ea4ed05c395f791f975b5946b2628e88357e67e9afb8e1902b67907c63d3bb
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
